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Viability is in the Eye of the Beholder. . .
Christopher M. Kramer, MD,* Jagat Narula, MD, PHD†T
he term myocardial “viability” in chronic left
ventricular (LV) dysfunction due to coronary
artery disease has been interpreted in multiple
ways by clinicians and imagers alike. The clas-
ic definition assesses whether or not the myocardial
issue under consideration is alive or dead. However,
ore often we have used the term to address
hether or not the tissue would recover function,
specially after revascularization. The variability of
maging definitions of viability further adds to the
roblem. The imaging definition of viability de-
ends upon the eye of the beholder. For example,
n echocardiographer defines viability as a preserved
ontractile response to low doses of dobutamine
LDD) or inotropic reserve. Those performing sin-
le-photon emission computed tomography (SPECT)
efine viability by the absolute number of counts
f myocardial perfusion tracers across a segment
f myocardium, or by the demonstration of redis-
ribution of radiotracer in the region of interest at
est. Positron emission tomography (PET) imag-
ng defines viability as a metabolically active tissue
ith adequate uptake of 18fluorodeoxyglucose
preferably in the presence of a severe reduction in
blood flow. Cardiac magnetic resonance (CMR)
identifies viability by documenting the lack of
transmural scarring across the thickness of the
myocardium—the less the transmurality of late
gadolinium enhancement (LGE), the more viable
the segment. In addition, inotropic reserve to
LDD has also been evaluated by CMR as a
marker of viability.
The variable definition of viability leads to the
variable predictive accuracy of these techniques for
functional recovery of dyskinetic myocardium af-
ter revascularization (1). Techniques that examine
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supported by NIH R01 HL075792.the inotropic reserve rather than perfusion, me-
tabolism, or scar transmurality tend to be more
specific because they examine the same endpoint
as that being measured at late follow-up. On the
other hand, the latter techniques tend to be more
sensitive, as the presence of preserved perfusion
and/or metabolism is necessary but not sufficient for
recovery of contractile function. This is borne out in
the elegant meta-analysis regarding CMR assessment
of viability by Romero et al. (2) in this issue of iJACC.
In this paper, the authors demonstrate in a meta-
analysis of 24 published CMR studies that LGE is
more sensitive for improved contractile function after
revascularization whereas LDD is more specific. They
argue that the combination of techniques might im-
prove overall accuracy of viability assessment. In fact,
this hypothesis has been validated in a small study of
patients undergoing coronary artery bypass grafting
(CABG) where LDD improved the per-segment
prediction of functional recovery in segments with 1%
to 50% transmurality of LGE (3). It is in these
segments in which there remains a question as seg-
ments with no LGE (viable) or 50% transmural
LGE (nonviable), the answer is generally clear (4).
The technical question regarding which test per-
forms best at predicting contractile recovery, al-
though of interest to imagers, may or may not be
the most clinically relevant question. This was borne
out in the STICH (Surgical Treatment for Ischemic
Heart Failure Trial) study of patients with ischemic
LV dysfunction in whom a group of patients who
did not improve ejection fraction post-CABG fared
no worse over time than those that did not (5). This
conundrum played out further in the viability sub-
study of STICH (6), which showed in a nonran-
domized fashion that viability status as defined by
optional SPECT or dobutamine echocardiography
did not predict death from cardiovascular causes.
The limitations and importance of this study are
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575highlighted in the iFORUM piece in this issue by
Chareonthaitawee and Gersh, and Panza (7). They
offer contrasting takes on the same data from both
the STICH viability trial and the PARR-2 (PET
and Recovery Following Revascularization) study
(8). Both studies demonstrated no influence of via-
ility on outcome. However, many of the clinicians
aring for the patients in the PARR-2 study did not
ollow the course that would be recommended based
n the viability findings by PET.
Clearly, viability is a complex issue. The
roper study of the utility of viability testingresponse and myocardial infarct trans
4
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304.ascularization or no revascularization depen-
ent upon and dictated by the viability findings
ather than be optional for both the testing and
ollowing of recommendations based on the
esting. Such a trial may never be performed.
or now we are left with the understanding
hat we can predict recovery of function in hi-
ernating myocardium using imaging but some
ivergence of opinion as to whether this has
ny relationship to ultimate clinical outcome.
s imagers, we certainly believe that it does,
ut we have not had the advantage of a defini-ould involve randomization of patients to re- tive study to prove the benefit of imaging.R E F E R E N C E S
1. Schinkel AFL, Poldermans D, Elhendy
A, Bax JJ. Assessment of myocardial
viability in patients with heart failure.
J Nucl Med 2007;48:1135–46.
2. Romero J, Xue X, Gonzalez W, Garcia
MJ. MR imaging assessing viability in
patients with chronic ventricular dys-
function due to coronary artery disease:
a meta-analysis of prospective trials.
J Am Coll Cardiol Img 2012;5:494–
508.
3. Bove CM, DiMaria JM, Voros S, Con-
away MR, Kramer CM. Dobutaminemurality: functional improvement af-
ter coronary artery bypass grafting—
initial experience. Radiology 2006;240:
835–41.
. Kim RJ, Wu E, Rafael A, et al. The use
of contrast-enhanced magnetic reso-
nance imaging to identify reversible
myocardial dysfunction. N Engl J Med
2000;343:1445–53.
. Samady H, Elefteriades JA, Abbott
BG, et al. Failure to improve left
ventricular function after coronary re-
vascularization for ischemic cardio-
myopathy is not associated with worse
outcome. Circulation 1999;100:1298–6. Bonow RO, Maurer G, Lee KL, et al.
Myocardial viability and survival in
ischemic left ventricular dysfunction.
N Engl J Med 2011;364:1617–25.
7. Chareonthaitawee P, Gersh BJ, Panza
JA. Is viability imaging still relevant in
2012? J Am Coll Cardiol Img 2012;5:
550–8.
8. Beanlands RSB, Nichol G, Huszti E,
et al. F-18-fluorodeoxyglucose positron
emission tomography imaging-assisted
management of patients with severe left
ventricular dysfunction and suspected
coronary disease: a randomized, con-
trolled trial (PARR-2). J Am Coll Car-
diol 2007;50:2002–12.
